01—Abstract
Summary
Summary of the 8-K filed October 23, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific (TMO) reported third quarter 2024 results for the fiscal quarter ended September 28, 2024.
Revenue was $10.60 billiona, essentially flat versus $10.57 billion in the prior-year quarter, though management said revenue growth, organic revenue growth and Core organic revenue growth all improved sequentially from Q2. GAAP diluted EPS was $4.25, down from $4.42, and GAAP operating margin slipped to 17.3% from 17.6%. Adjusted EPS was $5.28, down from $5.69 a year earlier, and adjusted operating margin contracted to 22.3% from 24.2%, driven largely by lower profitability in Laboratory Products and Biopharma Services (segment margin 13.5% vs. 16.4%).
On the balance sheet and cash flow side, nine-month operating cash flow rose to $5.38 billionb from $4.68 billion and free cash flow increased to $4.50 billion from $3.69 billion. The company spent $3.0 billion on share repurchases and $3.1 billion on acquisitions over the nine months, while cash and equivalents fell to $4.6 billion from $8.1 billion at year-end 2023, partly because of $2.0 billion placed into short-term investments. Goodwill rose to $46.7 billion, reflecting recent acquisitions.
Total debt (short-term plus long-term obligations) was roughly $35.3 billionc at quarter end. Management raised the low end of full-year 2024 adjusted EPS guidance to $21.35–$22.07 from $21.29–$22.07, and reaffirmed revenue guidance of $42.4–$43.3 billion.
The narrow guidance raise means the midpoint of adjusted EPS guidance moves only marginally, and the outlook implies a stronger fourth quarter than the year-to-date results alone would suggest. Investors should weigh the sequential improvement and cash generation against continued margin pressure and flat top-line growth.
02—Key points
Key Highlights
- Q3 2024 revenue of $10.60B was essentially flat year over year (vs. $10.57B), with organic and Core organic growth both flat but improved sequentially from Q2.
- GAAP diluted EPS fell to $4.25 from $4.42, and GAAP operating income declined to $1.84B from $1.86B.
- Adjusted EPS of $5.28 declined from $5.69, and adjusted operating margin compressed to 22.3% from 24.2%.
- Laboratory Products and Biopharma Services segment income margin fell to 13.5% from 16.4%, the main drag on profitability; Life Sciences Solutions margin rose to 35.4% in Q3 from 35.9%, while Analytical Instruments and Specialty Diagnostics were mixed.
- Nine-month free cash flow rose 22% to $4.50B from $3.69B, and operating cash flow increased to $5.38B from $4.68B.
- Full-year 2024 adjusted EPS guidance was narrowed upward to $21.35–$22.07 (from $21.29–$22.07); revenue guidance of $42.4–$43.3B was maintained.
- Capital deployment continued with $3.0B in share repurchases and $3.1B in acquisitions over nine months, while cash and equivalents declined to $4.6B from $8.1B.
03—Questions
Frequently Asked Questions
Did Thermo Fisher grow revenue in the third quarter of 2024?
Only marginally. Q3 2024 revenue was $10.60 billion versus $10.57 billion in Q3 2023, essentially flat. Management said growth, organic revenue growth and Core organic revenue growth all improved sequentially from the second quarter, but organic and Core organic growth were both flat year over year.
Why did profitability decline in the quarter?
Adjusted operating margin fell to 22.3% from 24.2%, and adjusted EPS dropped to $5.28 from $5.69. The filing points to weaker results in Laboratory Products and Biopharma Services, where segment margin fell to 13.5% from 16.4%. Higher SG&A expense (16.4% of revenue vs. 14.9%) also weighed on GAAP results, and interest income declined relative to the prior year's cash balances.
What changed in full-year 2024 guidance?
Adjusted EPS guidance was raised at the low end to $21.35–$22.07 from $21.29–$22.07, so the top end is unchanged. Revenue guidance was maintained at $42.4–$43.3 billion. The change is small, so the guidance still implies a meaningful step-up in the fourth quarter relative to the first nine months.
How is the company generating and using cash?
Free cash flow for the first nine months of 2024 was $4.50 billion, up from $3.69 billion, as operating cash flow improved to $5.38 billion and capital expenditures fell. Cash was used for $3.0 billion in share buybacks, $434 million in dividends, $3.1 billion in acquisitions, and $2.0 billion in short-term investments, reducing cash and equivalents to $4.6 billion.
Are there any notable product or strategic developments?
Management highlighted new launches including the Thermo Scientific Iliad scanning transmission electron microscope, the Applied Biosystems MagMAX Sequential DNA/RNA kit, and Invitrogen Vivofectamine Delivery Solutions. It also announced a partnership with the National Cancer Institute on the myeloMATCH precision medicine trial, expanded pharma services capacity in Cincinnati and Bend, and opened a new bioanalytical lab in Gothenburg, Sweden.
04—Continue